SCHEMBL6040899

SCHEMBL6040899

CCCCNC(=O)CI

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14231351 0.93 CASP2 (0.63)
SCHEMBL5501338 0.91 CASP2 (0.67)
SCHEMBL8973921 0.91 CASP2 (0.67)
SCHEMBL935157 0.91 CASP2 (0.67)
SCHEMBL933644 0.91 CASP2 (0.67)
SCHEMBL934477 0.91 CASP2 (0.67)
SCHEMBL28806490 0.91 CASP2 (0.67)
SCHEMBL10050997 0.85
SCHEMBL3465519 0.83
SCHEMBL1927840 0.82 ALDH1A1 (0.59)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118667812-A Compositions and methods for treating muscular atrophy and tonic muscular dystrophy 艾维迪提生物科学公司 2024-09-20 CN disclosed
CN-118638787-A Compositions and methods for treating muscular atrophy and tonic muscular dystrophy 艾维迪提生物科学公司 2024-09-13 CN disclosed
CN-118638788-A Compositions and methods for treating muscular atrophy and tonic muscular dystrophy 艾维迪提生物科学公司 2024-09-13 CN disclosed
CN-111902148-B Compositions and methods for treating muscular atrophy and tonic muscular dystrophy 艾维迪提生物科学公司 2024-07-05 CN disclosed
CN-118267396-A Nucleic acid-polypeptide compositions and uses thereof 艾维迪提生物科学公司 2024-07-02 CN disclosed
CN-118265544-A Compositions and methods for treating facial shoulder brachial muscular dystrophy 艾维迪提生物科学公司 2024-06-28 CN disclosed
CN-111655268-B Nucleic acid-polypeptide compositions and uses thereof 艾维迪提生物科学公司 2024-03-26 CN disclosed
EP-4262811-A1 TREATMENT WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CTLA-4 AND PD-1 INHIBITORS Iovance Biotherapeutics, Inc. (US) 2023-10-25 EP disclosed
US-20230270876-A1 SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES NOVARTIS AG (CH) 2023-08-31 US disclosed
CN-115666589-A Compositions and methods for treating facioscapulohumeral muscular dystrophy 艾维迪提生物科学公司 2023-01-31 CN disclosed
WO-2014116596-A1 METHODS FOR OPTIMIZING DOMAIN STABILITY OF BINDING PROTEINS ABBVIE, INC. (US) 2014-07-31 WO disclosed
US-20140065171-A1 Site-Specific Labeling Methods and Molecules Produced Thereby NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2014-03-06 US disclosed
WO-2013173756-A1 A METHOD FOR QUANTIFYING PROTEINS AND ISOFORMS THEREOF UNIVERSITY OF NORTH DAKOTA (US) 2013-11-21 WO disclosed
US-20110237503-A1 NOVEL PEPTIDES AND METHODS FOR THEIR PREPARATION AND USE ELI LILLY AND COMPANY (US) 2011-09-29 US disclosed
US-20060134103-A1 Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands HAWLEY STEPHEN B 2006-06-22 US disclosed
US-20060099150-A1 Compositions and methods for the transport of biologically active agents across cellular barriers HOUSTON L L 2006-05-11 US disclosed
US-20050100543-A1 Multivalent carriers of bi-specific antibodies IMMUNOMEDICS, INC. (US) 2005-05-12 US disclosed
EP-1034303-A1 METHODS OF DETECTING POLYNUCLEOTIDE ANALYTES Diasorin International Inc. (US) 2000-09-13 EP disclosed
WO-1999028503-A1 METHODS OF DETECTING POLYNUCLEOTIDE ANALYTES DIASORIN INTERNATIONAL INC. (US) 1999-06-10 WO disclosed
CN-1083485-A Benzo thia azepine and benzo oxa-azepine derivatives PFIZER (US) 1994-03-09 CN disclosed